Virologic characterization of symptom rebound following nirmatrelvir-ritonavir treatment for COVID-19

Julie Boucau; Rockib Uddin; Caitlin Marino; James Regan; Manish C Choudhary; James P Flynn; Geoffrey Chen; Ashley M Stuckwisch; Josh Mathews; May Y Liew; Arshdeep Singh; Zahra Reynolds; Surabhi L Iyer; Grace C Chamberlin; Tammy D Vyas; Jatin M Vyas; Sarah E Turbett; Jonathan Z Li; Jacob E Lemieux; Amy K Barczak; Mark J Siedner

Este artigo é um Preprint

Preprints são relatos preliminares de pesquisa que não foram certificados pela revisão por pares. Eles não devem ser considerados para orientar a prática clínica ou comportamentos relacionados à saúde e não devem ser publicados na mídia como informação estabelecida.

Preprints publicados online permitem que os autores recebam feedback rápido, e toda a comunidade científica pode avaliar o trabalho independentemente e responder adequadamente. Estes comentários são publicados juntamente com os preprints para qualquer pessoa ler e servir como uma avaliação pós-publicação.

Virologic characterization of symptom rebound following nirmatrelvir-ritonavir treatment for COVID-19

Julie Boucau; Rockib Uddin; Caitlin Marino; James Regan; Manish C Choudhary; James P Flynn; Geoffrey Chen; Ashley M Stuckwisch; Josh Mathews; May Y Liew; Arshdeep Singh; Zahra Reynolds; Surabhi L Iyer; Grace C Chamberlin; Tammy D Vyas; Jatin M Vyas; Sarah E Turbett; Jonathan Z Li; Jacob E Lemieux; Amy K Barczak; Mark J Siedner.

Afiliação

Julie Boucau; Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA
Rockib Uddin; Massachusetts General Hospital
Caitlin Marino; Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA
James Regan; Brigham and Women's Hospital
Manish C Choudhary; Brigham and Women's Hospital, Harvard Medical School
James P Flynn; Brigham and Women's Hospital
Geoffrey Chen; Massachusetts General Hospital
Ashley M Stuckwisch; Massachusetts General Hospital
Josh Mathews; Massachusetts General Hospital
May Y Liew; Massachusetts General Hospital
Arshdeep Singh; Massachusetts General Hospital
Zahra Reynolds; Massachusetts General Hospital
Surabhi L Iyer; Massachusetts General Hospital
Grace C Chamberlin; Massachusetts General Hospital
Tammy D Vyas; Massachusetts General Hospital
Jatin M Vyas; Massachusetts General Hospital, Harvard Medical School
Sarah E Turbett; Massachusetts General Hospital
Jonathan Z Li; Brigham and Women's Hospital, Harvard Medical School
Jacob E Lemieux; Massachusetts General Hospital, Harvard Medical School, Broad Institute
Amy K Barczak; Ragon Institute of MGH, MIT and Harvard, Massachusetts General Hospital, Harvard Medical School
Mark J Siedner; Massachusetts General Hospital, Harvard Medical School

Preprint em En | PREPRINT-MEDRXIV | ID: ppmedrxiv-22275326

ABSTRACT

ABSTRACT

We enrolled seven individuals with recurrent symptoms following nirmatrelvir-ritonavir treatment. High viral loads (median 6.1 log10 copies/mL) were detected at enrollment and for a median of 17 days after initial diagnosis. Three of seven had culturable virus for up to 16 days after initial diagnosis. No known resistance-associated mutations were identified.

Licença

cc_by_nc

Texto completo

Adicionar na Minha BVS

Imprimir

XML

Buscar no Google

Texto completo: 1 Coleções: 09-preprints Base de dados: PREPRINT-MEDRXIV Idioma: En Ano de publicação: 2022 Tipo de documento: Preprint

Texto completo

Adicionar na Minha BVS

Imprimir

XML

Buscar no Google

Texto completo: 1 Coleções: 09-preprints Base de dados: PREPRINT-MEDRXIV Idioma: En Ano de publicação: 2022 Tipo de documento: Preprint